Myasthenia gravis (MG) in children and adolescents to age 18 -- juvenile MG -- includes clinically significant developmental ...

Living with an autoimmune disease is linked to a near doubling in the risk of persistent mental health issues, such as ...

In this interview, Richard J. Nowak, MD, MS, principal investigator of the MINT trial of inebilizumab for generalized myasthenia gravis (gMG), discusses the trial’s key findings, including significant ...

MG was considered well-controlled if the patients had pharmacological remission or minimal manifestations of disease, according to the Myasthenia Gravis Foundation of America's (MGFA) clinical ...